Faculty Opinions recommendation of Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 72
◽
pp. S16
◽
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
2016 ◽
2020 ◽
Keyword(s):